home / stock / chrs / chrs quote
Last: | $2.39 |
---|---|
Change Percent: | 0.0% |
Open: | $2.42 |
Close: | $2.39 |
High: | $2.51 |
Low: | $2.36 |
Volume: | 2,092,588 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.39 | $2.42 | $2.39 | $2.51 | $2.36 | 2,092,588 | 03-28-2024 |
$2.42 | $2.32 | $2.42 | $2.44 | $2.28 | 2,583,955 | 03-27-2024 |
$2.3 | $2.32 | $2.3 | $2.39 | $2.285 | 4,936,909 | 03-26-2024 |
$2.28 | $2.33 | $2.28 | $2.4 | $2.26 | 1,921,134 | 03-25-2024 |
$2.33 | $2.48 | $2.33 | $2.49 | $2.32 | 2,085,061 | 03-22-2024 |
$2.51 | $2.52 | $2.51 | $2.64 | $2.47 | 3,270,172 | 03-21-2024 |
$2.48 | $2.4 | $2.48 | $2.555 | $2.35 | 3,858,924 | 03-20-2024 |
$2.45 | $2.21 | $2.45 | $2.48 | $2.18 | 3,412,719 | 03-19-2024 |
$2.22 | $2.22 | $2.22 | $2.26 | $2.135 | 2,545,264 | 03-18-2024 |
$2.22 | $2.18 | $2.22 | $2.28 | $2.17 | 3,529,733 | 03-15-2024 |
$2.17 | $2.1 | $2.17 | $2.55 | $2.05 | 6,163,960 | 03-14-2024 |
$2.3 | $2.25 | $2.3 | $2.38 | $2.17 | 3,054,265 | 03-13-2024 |
$2.24 | $2.28 | $2.24 | $2.355 | $2.22 | 2,214,003 | 03-12-2024 |
$2.27 | $2.37 | $2.27 | $2.45 | $2.24 | 1,911,997 | 03-11-2024 |
$2.39 | $2.23 | $2.39 | $2.55 | $2.23 | 5,088,486 | 03-08-2024 |
$2.21 | $2.22 | $2.21 | $2.245 | $2.13 | 3,019,748 | 03-07-2024 |
$2.21 | $2.23 | $2.21 | $2.32 | $2.19 | 1,893,022 | 03-06-2024 |
$2.18 | $2.25 | $2.18 | $2.25 | $2.15 | 2,085,033 | 03-05-2024 |
$2.27 | $2.54 | $2.27 | $2.54 | $2.25 | 3,087,485 | 03-04-2024 |
$2.41 | $2.33 | $2.41 | $2.465 | $2.27 | 2,293,474 | 03-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
NASDAQ Market:
Coherus BioSciences Inc. Website:
2024-03-14 18:28:43 ET The final set of results for Coherus Biosciences ' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock down by more than 6% Thursday, a much steeper fall than the 0.6...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fou...
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA ® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI ® net sales of $52.4 milli...